07:00 , Aug 10, 2009 |  BioCentury  |  Finance

Ebb & Flow

With six new deals last week, the summer's hot follow-on market now has raised $1.1 billion in 13 offerings during 3Q, with more than half the quarter still ahead. The 3Q09 deal flow comes on...
07:00 , May 19, 2008 |  BC Week In Review  |  Company News

Oncothyreon, Merck KGaA deal

Oncothyreon (formerly Biomira Inc. ) received a $3 million milestone payment from Merck KGaA under a 2001 development and commercialization agreement for Stimuvax. The payment was triggered by the transfer of additional assays and manufacturing...
07:00 , Apr 7, 2008 |  BioCentury  |  Strategy

Takeda fills a gap

Takeda Pharmaceutical Co. Ltd. 's decision last week to in-license Cell Genesys Inc. 's GVAX vaccine for prostate cancer is the first significant deal by a pharma company in the cancer immunotherapy space in about...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Company News

Oncothyreon, Merck KGaA deal

ONTY (formerly Biomira Inc. ) received a $5 million milestone payment from MRK under a 2001 deal to develop and market ONTY's Stimuvax cancer vaccine (see BioCentury, Aug. 13 & May 7, 2001). The payment...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

PX-866: Phase I start

Early next year, BIOM hopes to begin a Phase I trial. Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta   Product: PX-866   Business: Cancer   Molecular target: Not available   Description: Inhibitor of the PI-3-kinase/ PTEN...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Company News

CG Therapeutics board of directors update

CG Therapeutics Inc. , Seattle, Wash.   Business: Cancer   Appointed: Christopher Henney, chairman of Biomira Inc. and SGX Pharmaceuticals Inc. , as chairman  ...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Stimuvax: Updated Phase IIb data

Updated data from an open-label Phase IIb trial showed that 49% of patients with Stage IIIb locoregional disease who received Stimuvax plus standard care were alive after 3 years vs. 27% of patients receiving standard...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

PX-478: Phase I started

BRA began an open-label, dose-escalation, U.S. Phase I trial in 36 patients who failed or are intolerant with standard therapy to evaluate oral PX-478 given on days 1-5 during a 21-day cycle. Biomira Inc. (TSX:BRA;...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Company News

Biomira, Merck KGaA deal

The partners added Canada to MRK's license covering BRA's Stimuvax cancer vaccine. MRK now has worldwide rights to develop and market the liposomal vaccine containing a synthetic, 25-amino acid peptide sequence from MUC-1 ( CD227...
07:00 , Jul 23, 2007 |  BC Week In Review  |  Company News

Biomira management update

Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta   Business: Cancer   Hired: Gary Christianson as COO, formerly site director at GlaxoSmithKline plc 's biologics unit  ...